RenNano：fully human nanobody platform
RenNano mice contain full human antibody heavy chain variable regions and a modified constant region for the development of heavy-chain-only antibodies (HCAbs) or nanobodies.
Nano 100 Project
The “Nano 100 Project” aims to develop fully human nanobody drugs using RenNano mice for more than 100 targets, including tumor associated antigens (TAAs), GPCRs, immune-checkpoints, cytokines, and factors related to neurological diseases.
AACR 2023: RenNano® Mice: A Heavy-Chain-Only Antibody Platform for the Generation of Nanobody Therapeutics
AACR 2023: Discovery of RenNano®-Derived Human Heavy-Chain-Only Antibodies That Cross the Blood-Brain-Barrier